Has Bethlehem Zeleke, MD received payments from drug or device companies?

Yes. Drug and device makers reported $25,455 in general payments to Bethlehem Zeleke, MD across 77 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bethlehem Zeleke, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bethlehem Zeleke, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bethlehem Zeleke, MD

Cardiovascular Disease · Emeryville, CANPI 1467814145

Payments from drug & device makers

$25,455in general payments, 2019–2025

Across 77 payments — averaging $330.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$16K
Medtronic$5K
Boston Scientific$2K
Biosense Webster, Inc.$2K
Biotronik Inc.$426
Boehringer Ingelheim$118

What the payments were for

Grants$15,00059%
Travel & lodging$6,59226%
Food & beverage$2,89711%
Education$9664%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	44	$15,829
Medtronic	2	$5,128
Boston Scientific	13	$2,220
Biosense Webster, Inc.	16	$1,734
Biotronik Inc.	1	$426
Boehringer Ingelheim	1	$118

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,455 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Medicare billing

Part B allowed, 2024

$26,472

Medicare patients

136

Services billed

208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	15	$16,398
Atorvastatin Calcium	61	$1,025
Metoprolol Succinate	35	$422
Carvedilol	25	$370
Rosuvastatin Calcium	14	$137
Losartan Potassium	11	$46
Amlodipine Besylate	12	$22

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Emeryville

Ted LoveHillsborough$102.8M
Matthew BudoffTorrance$11.3M
Lori DanielsSan Diego$10.2M
Paul KurthSanta Barbara$6.1M
Michael BlumSan Francisco$5.5M
Tony ChouSan Francisco$5.2M
Jason RogersSacramento$5.1M
Yu-Ping WangStanford$3.8M
Yogesh PaliwalPomona$3.3M
Farhad RafiiWest Hills$3.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →